<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113136</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-19095</org_study_id>
    <secondary_id>R01CA204891-01</secondary_id>
    <secondary_id>NCI-2019-01855</secondary_id>
    <nct_id>NCT03113136</nct_id>
  </id_info>
  <brief_title>Examination of Low Wattage and High Wattage E-Cigarettes</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>Examination of Low Wattage and High Wattage E-Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the proposed study is to evaluate the effect of switching from&#xD;
      conventional cigarettes to either a LWe or HWe on smoking behavior, product use patterns and&#xD;
      continued use, as well as biomarkers of toxicant exposure and effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete change from conventional cigarettes</measure>
    <time_frame>Baseline, Week1, Week 4, Week 8, Week 12, Week 26, and Week 52</time_frame>
    <description>Timeline Follow Back Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete change from conventional cigarettes</measure>
    <time_frame>Baseline, Week1, Week 4, Week 8, Week 12, Week 26, and Week 52</time_frame>
    <description>Exhaled carbon monoxide of ≤10ppm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EC Dependence</measure>
    <time_frame>Week -1, Baseline, Week 1, Week 4, Week 8, Week 12, Week 26 and Week 52</time_frame>
    <description>Cigarette Dependence Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EC Likeability/Preference</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Cigarette Evaluation Scale; and EC modified-Cigarette Evaluation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EC Abuse Liability</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Drug Effects/Liking Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - NNAL</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Urinary total 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanol [NNAL] (ng/g creatinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - NNN</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Presence of urinary [pyridine-D4]NNN ([D4]NNN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - Total Nicotine Equivalents (TNE)</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Sum of nicotine and metabolites in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - Nicotine Metabolite Ratio</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Biomarker of nicotine clearance formed using the ratio of 2 nicotine metabolites (3'hydroxycotinine [3HC]/cotinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - Nickel and other relevant metals</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Metals and metalloids in saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - Cadmium and other relevant metals</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Metals and metalloids in saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - Lead and other relevant metals</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Metals and metalloids in saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - 8-iso-PGF2a</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Urinary biomarker of oxidative stress and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Exposure - PGEM</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Urinary biomarker of oxidative stress and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of Effect - q-PADDA</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 26, and Week 52</time_frame>
    <description>Quantifies DNA damage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">453</enrollment>
  <condition>Smoking, Cigarette</condition>
  <condition>Smoking, Tobacco</condition>
  <condition>Nicotine Dependence</condition>
  <condition>Exposure to Toxic Agent</condition>
  <arm_group>
    <arm_group_label>Low wattage E cigarette device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High wattage E cigarette device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual brand cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low wattage E cigarette device</intervention_name>
    <description>The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.</description>
    <arm_group_label>Low wattage E cigarette device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>HIgh wattage E cigarette device</intervention_name>
    <description>The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.</description>
    <arm_group_label>High wattage E cigarette device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual brand cigarette</intervention_name>
    <description>The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.</description>
    <arm_group_label>Usual brand cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. smoke ≥5 cigarettes per day for the past year;&#xD;
&#xD;
          2. no quit attempt in the prior 3 months and no plan to quit in the next 3 months;&#xD;
&#xD;
          3. read, write, and speak in English;&#xD;
&#xD;
          4. report at least minimal interest in switching to an alternative product (&gt; &quot;not at&#xD;
             all&quot; on a Likert scale);&#xD;
&#xD;
          5. never purchased or regularly used a tank system, mechanical mod, or advanced personal&#xD;
             vaporizer EC, though previous use of cig-a-like devices will be allowed but not in the&#xD;
             last 3 months;&#xD;
&#xD;
          6. plan to live in the local area for next year; and&#xD;
&#xD;
          7. have reliable means of transport. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &lt;18 years old;&#xD;
&#xD;
          2. unstable or significant medical condition such as respiratory, kidney, or liver&#xD;
             disease that could potentially affect biomarker data;&#xD;
&#xD;
          3. unstable or significant psychiatric conditions (past and stable conditions will be&#xD;
             allowed);&#xD;
&#xD;
          4. history of cardiac event or distress within the past 3 months; and&#xD;
&#xD;
          5. currently pregnant, planning to become pregnant, or breastfeeding (n.b: pregnancy&#xD;
             status will continue to be evaluated throughout the study at each visit).&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Wagener, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Wagener, PhD</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>44350</phone_ext>
      <email>theodore-wagener@ouhsc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Theodore Wagener</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

